Degron Therapeutics Raises $22M Series A Financing To Accelerate Growth And Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

Jun 09, 2022•over 3 years ago

Amount Raised

$22 Million

Round Type

series a

Description

Degron Therapeutics ("Degron"), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets, today announced it has closed a $22 million Series A financing round led by Med-Fine Capital. Additional investors participating in the financing round included Dyee Capital, Baidu Venture, and NeuX Capital, along with Degron's seed investors, CO-WIN Ventures and Yuanbio Venture Capital.

Company Information

Company

Degron Therapeutics

About

Degron Therapeutics is a biotechnology company advancing human health by developing novel medicines using its robust molecular glue-based targeted protein degradation drug discovery platform. The company's unique GlueXplorer® platform has created a rapidly expanding IP-protected compound library and screening system to develop a new class of small-molecule medicines that target previously undruggable disease targets. The company's pipeline includes a growing number of preclinical compounds for oncology, inflammation, metabolic disease, and rare diseases. For more information, please visit www.degrontx.com. SOURCE Degron Therapeutics

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Degron Therapeutics Raises $22M Series A Financing To Accelerate Growth And Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information